Safety and Antitumour Activity of Setidegrasib in Patients with Previously Treated Advanced KRAS p.G12D-mutated NSCLC and PADC By Ogkologos - April 13, 2026 144 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a first-in-human phase I study Source RELATED ARTICLESMORE FROM AUTHOR Mezigdomide-Carfilzomib-Dexamethasone Prolongs PFS Compared with Carfilzomib-Dexamethasone at First Relapse in Patients with Relapsed Or Refractory Multiple Myeloma FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive Bladder Cancer Systemic Aging Associated with a Higher Risk of Early-Onset Solid Cancers MOST POPULAR Lack of Immunity Against SARS-CoV-2 in a Large Tertiary Care Centre... September 2, 2020 Post-Mastectomy Boutique Set to Close After 12 Years, As Owner Has... March 12, 2019 Estimate of the Global Economic Cost of the Most Prevalent Cancers... March 13, 2023 Breast Cancer Survivor Earned Yoga Instructor Certification During Chemo. Now She... May 8, 2019 Load more HOT NEWS Aspartame and cancer – sweet nothings? Handmade Artisan Gifts For Under $30 Longest Follow-Up of CAR T-Cell Therapy in Mantle Cell Lymphoma Points... Electronic Symptom Monitoring with PROs Improves Patient-Reported Physical Function, Symptom Control,...
